BCL2 and acute myeloid leukemia: In the past few years, there has been a rapid shift toward the use of oral small-molecule and targeted therapies in AML, including the approval by the FDA of the BCL-2 inhibitor venetoclax in combination with HMA or LDAC in elderly (≥75 years) patients or those with comorbidities that preclude intensive induction in newly diagnosed AML.